32361-76-5

Upstream product

• 620-95-1 3-benzylpyridine 

Downstream Products

• 110141-52-1 (4-nitro-phenyl)-[3]pyridyl ketone 
• 85666-15-5 4-(3'-Pyridinylmethyl)aniline 
• 178809-75-1 4-(1-hydroxy-1-(4-pyridyl)methyl)-1-nitrobenzene 
• 85666-17-7 furegrelate sodium 
• 85666-43-9 3-bromo-2-hydroxy-5-(3-pyridylmethyl)benzaldehyde 
• 85666-04-2 3-(3-formyl-4-hydroxybenzyl)pyridine 
• 75987-20-1 3-(4'-Hydroxybenzyl)pyridine 
• 62-23-7 4-nitro-benzoic acid 

Relevant academic research and scientific papers

INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

Affinity of 3-acyl substituted 4-quinolones at the benzodiazepine site of GABAA receptors

The finding that alkyl 1,4-dihydro-4-oxoquinoline-3-carboxylate and N-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxamide derivatives may be high-affinity ligands at the benzodiazepine binding site of the GABAA receptor, prompted a study of 3-acyl-1,4-dihydro-4-oxoquinoline (3-acyl-4-quinolones). In general, the affinity of the 3-acyl derivatives was found to be comparable with the 3-carboxylate and the 3-carboxamide derivatives, and certain substituents (e.g., benzyl) in position 6 were again shown to be important. As it is believed that the benzodiazepine binding site is situated between an α- and a γ-subunit in the GABAA receptor, selected compounds were tested on the α1β2γ2s, α2β2γ2s and α3β2γ2s GABAA receptor subtypes. The 3-acyl-4-quinolones display various degrees of selectivity for α1- versus α2- and α3-containing receptors, and high-affinity ligands essentially selective for α1 over α3 were developed.

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS

This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their the use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy.

Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors

This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.